Biotech meets demography meets (as always) finance

Brandon Kein initiates the discussion about the possible costs of future life-extending therapies. Add to that the grim outlook of fiscal and pension systems even assuming no revolutionary breakthroughs in biotech, and you have the recipe for interesting times ahead.